Previous 10 | Next 10 |
Dividends can fund a wonderful retirement. Today, we look at two amazing benefits that only dividends can provide. It's time to consider a change to dividends. For further details see: Yes, You Can Retire On Dividends
NASHVILLE, Tenn., June 17, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $20 million aggregat...
Harrow Health (HROW) has priced its public offering of $17.5M of 8.625% senior notes due 2026.The Notes will be sold at $25.75/Note, for aggregate gross proceeds of ~$18.03M, will be treated as a single series and will trade interchangeably with the existing notes.Underwriters are granted an ...
NASHVILLE, Tenn., June 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the pricing of its underwritten registered public offering of $17.5 million aggreg...
Harrow Health (HROW) has commenced an underwritten registered public offering of $17.5M of its 8.625% senior notes due 2026.The Notes will be treated as a single series with the Company’s outstanding 8.625% senior notes due 2026 and will trade interchangeably with the existing notes....
NASHVILLE, Tenn., June 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that it has commenced an underwritten registered public offering of $17.5 million ...
NASHVILLE, Tenn., June 03, 2021 (GLOBE NEWSWIRE) -- Visionology, a subsidiary of Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it had acquired a worldwide exclusive license from Spaeth/Richman Contrast Sensitivity Center (SPARCS) to ...
NASHVILLE, Tenn., June 01, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the launch of its newly redesigned corporate and investor website, harrowinc.com...
HROWL yields 8.3% and has outstanding call protection. HROW has more cash and marketable securities than debt. HROW reported blowout Q1 earnings and the stock has nearly doubled over the last year. The $55 million of HROWL debt is dwarfed by the $250 million equity market capi...
NASHVILLE, Tenn., May 17, 2021 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business and a wholly owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced that a study of its Klarity-C Dro...
News, Short Squeeze, Breakout and More Instantly...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...